Quantcast

Latest Gilead Sciences Stories

2014-10-22 16:28:46

FLINT, Mich., Oct. 22, 2014 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni(® )(ledipasvir/sofosbuvir) product was approved for the treatment of chronic hepatitis C, genotype 1 infection in adults. Harvoni(®) is the first oral combination therapy approved for the treatment of hepatitis C and is also the first treatment regimen that does not require administration with pegylated interferon or ribavirin....

2014-10-22 12:30:21

VANCOUVER, BC and PLYMOUTH, MI, Oct. 22, 2014 /PRNewswire/ - ProNAi Therapeutics Inc., a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi® platform, today announced that it has added five seasoned executives to its senior management team. -- Dr. Angie You, Chief Business & Strategy Officer & Head of Commercial -- Wendy Chapman, Senior Vice President, Clinical Operations...

2014-10-20 08:32:35

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 20, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding AbbVie Inc. (NYSE: ABBV), Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:...

2014-10-15 08:30:48

BURLINGAME, Calif., Oct. 15, 2014 /PRNewswire/ -- Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, today announced the appointments of Ovid C. Trifan, MD, PhD as Vice President, Clinical Development and Amy Wong as Vice President, Finance. Dr. Trifan joins Apexigen from Onyx Pharmaceuticals with extensive expertise in oncology research and product development. Ms. Wong...

2014-10-10 16:24:32

Provides use, cost forecast based on testing, future treatment rates ST. PAUL, Minn., Oct. 10, 2014 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of Gilead's new, fixed-dose, combination Hepatitis C drug signals another spike in treatment and pharmacy costs for health plans across the country, according to Prime Therapeutics LLC (Prime). "When Sovaldi launched earlier this year, we saw a dramatic increase in prescriptions for the drug," said Peter Wickersham, senior...

2014-09-29 08:30:22

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to...

2014-09-29 04:21:31

BEERSE, Belgium, September 29, 2014 /PRNewswire/ -- CHMP also issues two label extensions for darunavir Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA(TM) (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1...

2014-09-25 12:29:32

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry,...

2014-09-25 08:26:56

GENEVA, September 25, 2014 /PRNewswire/ -- MPP signs sub-licences with six generic manufacturers for the development of Phase III drug Tenofovir Alafenamide Two months after signing a licence with Gilead Sciences, Inc. for the company's novel investigational medicine tenofovir alafenamide (TAF), MPP announced six new sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs to allow generic manufacture of TAF for...

2014-09-24 16:26:27

ReportsnReports.com offers Bronchopulmonary Dysplasia - Pipeline Review, H2 2014 and Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2014 new market reports. These reports provide an overview of the Bronchopulmonary Dysplasia's and Respiratory Syncytial Virus (RSV) Infections therapeutic pipeline. DALLAS, Sept. 24, 2014 /PRNewswire-iReach/ -- These reports provide comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia and Respiratory...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related